HOME >> MEDICINE >> NEWS
Specialty medical societies offer evidence-based conclusions on inhaled steroid treatment for asthma

(NORTHBROOK, IL, December 9, 2003) - Inhaled corticosteroid (ICS) therapy remains the gold standard of asthma treatment, according to findings from a systematic evidence review released today by the American College of Chest Physicians (ACCP), the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Allergy, Asthma, and Immunology (ACAAI). Published in the December issue of CHEST, the peer-reviewed journal of the ACCP, the review offers evidence-based conclusions on several prominent risks associated with ICS therapy for the treatment of adult and pediatric asthma.

"ICS therapy has been the gold standard in asthma treatment for 20 years because of its proven effectiveness. However, since the inception of ICS therapy, physicians have been concerned about side effects, particularly in special populations, such as children, women, and the elderly," said lead author Frank T. Leone, MD, MS, FCCP, Thomas Jefferson University, Philadelphia, PA. "After a systematic and accurate review of the proven risks, we can say with confidence that the majority of evidence supports the conclusion that the clinical effectiveness of ICS therapy decidedly outweighs the proven risks."

An expert panel with representatives from the ACCP, the AAAAI, and the ACAAI identified critical questions that impact decisions regarding the use of ICS therapy in relation to the five adult and pediatric risk areas of bone mineral density (BMD), cataracts, glaucoma, growth retardation, and skin thinning. Panel members reviewed 108 asthma studies related to ICS therapy complications and summarized all relevant evidence for each risk area. A consensus statement was provided for each risk area along with a grade to reflect the quantity and quality of evidence supporting each conclusion. Overall, the panel concluded that the benefits associated with ICS use greatly exceed the risks. In regards to the effect of ICS therapy on BMD, the panel stro
'"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
8-Dec-2003


Page: 1 2

Related medicine news :

1. Rigorous Evaluation Of "Hospitalist" Model Needed To Determine Impact Of This New Medical Specialty, According To UCSF Health Policy Researchers
2. Advertising by academic medical centers may risk eroding public trust, says study
3. NIH state-of-the-science panel calls for demedicalization of menopause
4. Community care tops medical care at preventing heart disease in black Americans
5. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
6. Jefferson Lab medical imager spots breast cancer
7. Society of Hospital Medicine to launch new medical journal
8. LA BioMed medical/research briefs March 2005
9. Promising new strategy for Swedish medical research
10. Flu vaccination benefits people of any age with high-risk medical conditions
11. UCLA study: Nearly a third of drug ads in medical journals contain no references for medical claims

Post Your Comments:
(Date:12/22/2014)... (PRWEB) December 22, 2014 The founders ... BLS and ACLS online certification provider, are proud to ... . The updated site now features a more user-friendly ... ever to use. , As a company spokesperson ... is now consolidated into a single page during the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The holidays are ... of the season. Many may be thinking about how to ... of a few weeks. Health Republic Insurance of New York ... Dietitian, Andrea Chernus, to provide some smart ideas to enjoy ... healthy. , 1)    Avoid arriving at a holiday gathering over-hungry , ...
(Date:12/22/2014)... U.S. and state health officials are investigating a listeria ... least four people and sickened 28 others in 10 ... prepackaged caramel apples until more information becomes available, the ... a news release. As of Dec. 18, a ... outbreak strains of the bacteria Listeria monocytogenes . ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Physicians in ... (rituximab) for the treatment of non-Hodgkin’s lymphoma (NHL), according ... a leading global healthcare consulting firm. MabThera is the ... (DLBCL), the most common form of NHL. , According ... and Barriers,” the incidence of NHL in China has ...
(Date:12/22/2014)... 22, 2014 Super Saturday, the last ... year as the busiest day in the 2014 holiday ... Grass Station had a steady pre-Christmas stream of customers, ... past Saturday. , “I definitely intend to take advantage…of ... Denver resident who was enjoying The Grass Station’s holiday ...
Breaking Medicine News(10 mins):Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:CDC Warns of Listeria Danger From Caramel Apples 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 Swedish ... Inc. today announced that the Committee for Medicinal Products ... (EMA) has adopted a positive opinion for the use ... adult men with Peyronie,s disease with a palpable plaque ... the start of therapy. The use of ...
(Date:12/22/2014)... Maine , Dec. 22, 2014  Mark ... analysis brief providing a summary of the 2015 ... plan enrollment trends.  According to ... for Planning and Evaluation, Department of Health and ... were enrolled in individual medical plans through the ...
(Date:12/22/2014)... 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) today ... has been filed and is now open and that ... Department of Health and Human Services (HHS), through the ... "We are extremely pleased to have the IND now ... a significant milestone in our company,s partnership with BARDA ...
Breaking Medicine Technology:Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
Cached News: